Bailes new ASCO Foundation chair

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

Bailes new ASCO Foundation chair

ALEXANDRIA, Virginia—Joseph Bailes, MD, editor of Cancer Care & Economics, has been named the new chair of the board of directors of The ASCO Foundation, which works with ASCO to raise and distribute funds for programs that improve cancer care and create an environment for prevention and cure.

A former president of ASCO from 1999 to 2000, Dr. Bailes is a nationally recognized leader in cancer public policy and will continue to serve as co-chair of the ASCO Government Relations Council.

"This is an exciting time in the field of clinical oncology as cancer research and treatments continue to progress, and we are helping to improve the lives of those living with cancer," Dr. Bailes said. "Working with The ASCO Foundation's remarkable staff and board of directors is a wonderful opportunity, and I look forward to supporting continued advancement in the field of oncology in my new role as chair."

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content